NCT01419834 2023-08-04
Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
Clinical Trials
6 trialsNCT00492167 2022-03-07
Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02130869 2017-12-22
A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00743496 2017-08-17
A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00450307 2013-10-16
Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00037011 2013-01-18
Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed